文献速递病毒性肝炎艾滋病与性传播感染

近期注射吸毒或接受阿片激动剂治疗者丙肝DAA治疗依从性研究

Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.
PubMed 文献 · Clin Infect Dis · 2020-01-01

SIMPLIFY和D3FEAT两项国际多中心研究纳入190例近期注射吸毒或当前接受阿片激动剂治疗的丙肝患者,比较每日一次与每日两次直接抗病毒药物(DAA)治疗的依从性。

要点

  • 近期兴奋剂注射、不稳定住房和每日两次给药与非依从性独立相关。
  • 依从性<90%或连续漏服7次未显著降低持续病毒学应答率。

核心结论

  • 近期注射吸毒或接受阿片激动剂治疗者中,每日一次和每日两次DAA治疗均呈现高依从性。
  • 观察到的非依从未影响治疗结局,提示DAA方案对非依从具有宽容性。

研究设计与样本

  • SIMPLIFY和D3FEAT为国际多中心研究,2016年3月至2017年2月在8个国家招募近期注射吸毒(过去6个月)或当前接受阿片激动剂治疗的参与者。
  • 共纳入190例参与者,接受索磷布韦/维帕他韦(每日一次)或帕利瑞韦/利托那韦/奥比他韦联合达萨布韦(每日两次)±利巴韦林治疗12周,使用电子泡罩包装监测。

主要发现

  • 184例(97%)完成治疗,中位依从性为92%。
  • 40%(n=76)参与者依从性<90%。
  • 近期兴奋剂注射(OR 2.48,95%CI 1.28-4.82)、不稳定住房(OR 2.18,95%CI 1.01-4.70)和每日两次给药(OR 2.81,95%CI 1.47-5.36)与非依从性相关。

临床怎么用

  • 对近期注射吸毒或接受阿片激动剂治疗的丙肝患者,可优先考虑每日一次DAA方案以提高依从性。
  • 需关注近期兴奋剂注射和不稳定住房等非依从风险因素,但非依从不一定影响疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study investigated adherence and associated factors among people with recent injection drug use (IDU) or current opioid agonist therapy (OAT) and compared once-daily to twice-daily hepatitis C virus (HCV) direct-acting antiviral (DAA) therapy. METHODS: SIMPLIFY and D3FEAT are international, multicenter studies that recruited participants with recent IDU (previous 6 months; SIMPLIFY, D3FEAT) or current OAT (D3FEAT) between March 2016 and February 2017 in 8 countries. Participants received sofosbuvir/velpatasvir (once daily; SIMPLIFY) or paritaprevir/ritonavir/ombitasvir, dasabuvir (twice daily) ± ribavirin (D3FEAT) for 12 weeks administered in electronic blister packs. We evaluated overall adherence (proportion of prescribed doses taken) and nonadherence (<90% adherent) between dosing patterns. RESULTS: Of 190 participants, 184 (97%) completed treatment. Median adherence was 92%, with higher adherence among those receiving once-daily vs twice-daily therapy (94% vs 87%, P = .005). Overall, 40% of participants (n = 76) were nonadherent (<90% adherent). Recent stimulant injecting (odds ratio [OR], 2.48 [95% confidence interval {CI}, 1.28-4.82]), unstable housing (OR, 2.18 [95% CI, 1.01-4.70]), and twice-daily dosing (OR, 2.81 [95% CI, 1.47-5.36]) were associated with nonadherence. Adherence decreased during therapy. Sustained virologic response was high in nonadherent (89%) and adherent populations (95%, P = .174), with no difference in SVR between those who did and did not miss 7 consecutive doses (92% vs 93%, P = .897). CONCLUSIONS: This study demonstrated high adherence to once- and twice-daily DAA therapy among people with recent IDU or currently receiving OAT. Nonadherence described did not impact treatment outcomes, suggesting forgiveness to nonadherence.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cunningham EB, Hajarizadeh B, Amin J, et al. Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. Clin Infect Dis. 2020. PMID: 31677262. doi:10.1093/cid/ciz1089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。